Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

November 12, 2018

Primary Completion Date

March 13, 2020

Study Completion Date

July 28, 2020

Conditions
Atopic Dermatitis
Interventions
DRUG

REGN3500

Administered subcutaneous (SC) every 2 weeks (q2w)

DRUG

Dupilumab

Administered SC q2w

DRUG

REGN3500 + Dupilumab Combo

Administered SC q2w

DRUG

Placebo

Administered SC q2w

Trial Locations (66)

1070

Regeneron Research Site, Anderlecht

1090

Regeneron Research Site, Brussels

1200

Regeneron Research Site, Brussels

2650

Regeneron Research Site, Antwerp

4000

Regeneron Research Site, Liège

6280

Regeneron Research Site, Loverval

10022

Regeneron Research Site, New York

10029

Regeneron Research Site, New York

10467

Regeneron Research Site, The Bronx

11375

Regeneron Research Site, Forest Hills

12459

Regeneron Research Site, Berlin

13496

Regeneron Research Site, Gyeonggi-do

13620

Regeneron Research Site, Gyeonggi-do

14584

Regeneron Research Site, Gyeonggi-do

15213

Regeneron Research Site, Pittsburgh

15706

Regeneron Research Site, Santiago de Compostela

15831

Regeneron Research Site, Mahlow

16499

Regeneron Research Site, Gyeonggi-do

18450

Regeneron Research Site, Gyeonggi-do

20537

Regeneron Research Site, Hamburg

20850

Regeneron Research Site, Rockville

21431

Regeneron Research Site, Incheon

21565

Regeneron Research Site, Incheon

22332

Regeneron Research Site, Incheon

22391

Regeneron Research Site, Hamburg

23220

Regeneron Research Site, Richmond

23538

Regeneron Research Site, Lübeck

27262

Regeneron Research Site, High Point

30328

Regeneron Research Site, Sandy Springs

33328

Regeneron Research Site, Davie

48084

Regeneron Research Site, Troy

48149

Regeneron Research Site, Münster

48455

Regeneron Research Site, Bad Bentheim

48706

Regeneron Research Site, Bay City

48903

Regeneron Research Site, Barakaldo

49085

Regeneron Research Site, Saint Joseph

58453

Regeneron Research Site, Witten

63450

Regeneron Research Site, Hanau

72076

Regeneron Research Site, Tübingen

73071

Regeneron Research Site, Norman

76014

Regeneron Research Site, Arlington

80337

Regeneron Research Site, München

85259

Regeneron Research Site, Phoenix

90025

Regeneron Research Site, Los Angeles

90033

Regeneron Research Site, Los Angeles

90808

Regeneron Research Site, Long Beach

92708

Regeneron Research Site, Fountain Valley

95815

Regeneron Research Site, Sacramento

97239

Regeneron Research Site, Portland

602 00

Regeneron Research Site, Brno

530 02

Regeneron Research Site, Pardubice

110 00

Regeneron Research Site, Prague

130 00

Regeneron Research Site, Prague

06120

Regeneron Research Site, Halle

04103

Regeneron Research Site, Leipzig

06484

Regeneron Research Site, Quedlinburg

85-065

Regeneron Research Site, Bydgoszcz

85-796

Regeneron Research Site, Bydgoszcz

38-440

Regeneron Research Site, Iwonicz-Zdrój

30-033

Regeneron Research Site, Krakow

90-436

Regeneron Research Site, Lodz

51-685

Regeneron Research Site, Wroclaw

03080

Regeneron Research Site, Seoul

03722

Regeneron Research Site, Seoul

06591

Regeneron Research Site, Seoul

07441

Regeneron Research Site, Seoul

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT03736967 - Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter